T Cell News and Research

Latest T Cell News and Research

Protein parkin essential for hypothalamic neurons recovery in Parkinson's disease patients

A Michigan State University researcher is working to uncover how a protein known as parkin may help nerve cells fight off damage from Parkinson's disease, a strategy that could lead to new therapies for the degenerative ailment.

23 Jul 2010

Drugs that activate SIRT1 hold potential to combat Alzheimer's: Study

MIT biologists report that they have discovered the first link between the amyloid plaques that form in the brains of Alzheimer's patients and a gene previously implicated in the aging process, SIRT1.

23 Jul 2010

Bristol-Myers Squibb second-quarter net sales increase 2% to $4.8 billion

Bristol-Myers Squibb Company today reported results for the second quarter of 2010 which featured data on key marketed and investigational compounds in its oncology, diabetes and cardiovascular franchises, and growth in sales and EPS. The company also confirmed guidance for 2010 and minimum guidance for non-GAAP EPS in 2013.

22 Jul 2010

Merrimack, sanofi-aventis initiate dosing in MM-121 and exemestane combination Phase 2 breast cancer study

Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today that the first patient has received an initial dose in a Phase 2 randomized double blind clinical study combining MM-121 with exemestane (Aromasin®) in breast cancer patients.

22 Jul 2010

Towards a cure: HIV reservoirs and strategies to control them

Can HIV infection ever be cured? The prospect of efficiently controlling HIV persistence in infected persons was the topic of a high-level, two-day meeting of researchers gathered here on the eve of AIDS 2010, the biennial international conference of HIV researchers, funders, policy-makers and advocates.

22 Jul 2010

BioTime announces 21 new stem cell products for sale

BioTime, Inc. announced today that on August 1, 2010 the Company will be offering for sale 21 new stem cell products for research use only. These products will include the novel stem cell lines: E120 expressing the gene LGR5 useful in colon cancer drug discovery, EN16, T43, RAD20.5, RA-SKEL8, SM22, and Z1, full properties of which will be disclosed on product launch, along with differentiation kits and media for the culture of each line.

22 Jul 2010

Genomics researchers study role of protein in metabolic disorders, heart disease

Studying a protein already known to play an important role in type 2 diabetes and cancer, genomics researchers have discovered that it may have an even broader role in disease, particularly in other metabolic disorders and heart disease. In finding unsuspected links to other disease-related genes, the scientists may have identified future targets for drug treatments.

22 Jul 2010

Scientists uncover new mechanism that reduces risk of type 2 diabetes, cardiovascular disease

In a joint study, scientists from The Scripps Research Institute and the Dana-Farber Cancer Institute at Harvard University have uncovered a novel mechanism that dramatically increases insulin sensitivity and reduces the risk of developing type 2 diabetes and cardiovascular disease.

22 Jul 2010

GE, MSKCC launch colon cancer study

A team of scientists at GE Global Research, the technology development arm for the GE, has launched a study with Memorial Sloan-Kettering Cancer Center, (MSKCC) one of the world's premier cancer centers, to better understand the early stages of colon cancer. The goal is to yield new insights that improve treatment selection and outcomes for cancer patients in the future.

22 Jul 2010

Affymetrix launches QuantiGene ViewRNA Assay formats

Affymetrix, Inc. today announced the launch of QuantiGene® ViewRNA Assay formats, which enable a new era of "in situ multiplex gene expression analysis" by allowing drug screening of native cells and advancing the pace of biomarker disease research and stem cell studies. These in situ assays enable researchers to visualize gene expression in individual cells at an unprecedented level of sensitivity and speed.

22 Jul 2010

TCF7L2 protein may play important role in heart disease, other metabolic disorders: Researchers

22 Jul 2010

New research identifies stem cells that generate three critical classes of nerve cells

New research, published in the journal Development, by Dr. Anthony-Samuel LaMantia, professor of Pharmacology & Physiology and director of the newly formed GW Institute for Neuroscience, and his colleagues have identified the stem cells that generate three critical classes of nerve cells - olfactory receptors, vomeronasal and gonadotropin releasing hormone neurons - that are responsible for enabling animals and humans, to eat, interact socially and reproduce.

22 Jul 2010

Onconase, Amphinase 2 show positive results for SARS virus: Tamir Biotechnology

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases confirmed that testing of two (2) of the company's compounds Onconase (Ranpirnase), and recombinant Amphinase 2 showed positive in vitro results for Severe Acute Respiratory Syndrome, also known as (SARS) virus.

22 Jul 2010

Study links application of disinfectants in recreational pools to adverse health outcomes

Splashing around in a swimming pool on a hot summer day may not be as safe as you think. A recent University of Illinois study links the application of disinfectants in recreational pools to previously published adverse health outcomes such as asthma and bladder cancer.

22 Jul 2010

Amylin reports $164.4M total revenue for quarter ended June 30, 2010

Amylin Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2010. The Company reported total revenue of $164.4 million for the quarter ended June 30, 2010, which includes net product sales of $162.5 million. Net loss, excluding a restructuring charge of $3.4 million, was $40.8 million, or $0.28 per share.

22 Jul 2010

Valproic acid halts vision loss in patients with retinitis pigmentosa

Researchers at the University of Massachusetts Medical School believe they may have found a new treatment for retinitis pigmentosa, a severe neurodegenerative disease of the retina that ultimately results in blindness. One of the more common retinal degenerative diseases, RP is caused by the death of photoreceptor cells and affects 1 in 4,000 people in the United States. RP typically manifests in young adulthood as night blindness or a loss of peripheral vision and in many cases progresses to legal blindness by age 40.

22 Jul 2010

Affymetrix second-quarter total revenue decreases to $71.7 million

Affymetrix, Inc., today reported its operating results for the second quarter of 2010. Total revenue for the quarter was $71.7 million, in line with previously announced expectations, as compared to total revenue of $81.6 million in the second quarter of 2009.

22 Jul 2010

Genzyme second-quarter revenue decreases to $1.08 billion

Genzyme Corp. today reported that second-quarter revenue was $1.08 billion, compared with $1.23 billion in the same period last year, reflecting limited shipments of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) due to product supply constraints in 2010. The company expects to be able to increase shipments of Cerezyme and Fabrazyme during the second half of the year.

21 Jul 2010

New insights on early pathogenic events, strategies for preventing HIV infection

In a plenary lecture at the 18th International AIDS conference in Vienna, Austria, Anthony S. Fauci, M.D., will present new insights on the early and complex pathogenic events that occur rapidly-within hours to days-following sexual exposure to HIV.

21 Jul 2010

Health Canada grants Osiris Priority Review for Prochymal NDS

Osiris Therapeutics, Inc. announced today that the Biologics and Genetic Therapies Directorate of Health Canada has completed its initial evaluation and accepted for full review the company's New Drug Submission (NDS) of Prochymal (remestemcel-L), an adult stem cell therapy for the treatment of graft vs. host disease (GvHD). Based on a separate review of summary clinical data, Health Canada has notified Osiris that the application has been granted Priority Review, shortening the examination period from 300 to 180 days.

21 Jul 2010

T Cell News and Research

Latest T Cell News and Research

Protein parkin essential for hypothalamic neurons recovery in Parkinson's disease patients

Drugs that activate SIRT1 hold potential to combat Alzheimer's: Study

Bristol-Myers Squibb second-quarter net sales increase 2% to $4.8 billion

Merrimack, sanofi-aventis initiate dosing in MM-121 and exemestane combination Phase 2 breast cancer study

Towards a cure: HIV reservoirs and strategies to control them

BioTime announces 21 new stem cell products for sale

Genomics researchers study role of protein in metabolic disorders, heart disease

Scientists uncover new mechanism that reduces risk of type 2 diabetes, cardiovascular disease

GE, MSKCC launch colon cancer study

Affymetrix launches QuantiGene ViewRNA Assay formats

TCF7L2 protein may play important role in heart disease, other metabolic disorders: Researchers

New research identifies stem cells that generate three critical classes of nerve cells

Onconase, Amphinase 2 show positive results for SARS virus: Tamir Biotechnology

Study links application of disinfectants in recreational pools to adverse health outcomes

Amylin reports $164.4M total revenue for quarter ended June 30, 2010

Valproic acid halts vision loss in patients with retinitis pigmentosa

Affymetrix second-quarter total revenue decreases to $71.7 million

Genzyme second-quarter revenue decreases to $1.08 billion

New insights on early pathogenic events, strategies for preventing HIV infection

Health Canada grants Osiris Priority Review for Prochymal NDS

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in